| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/424465 |
| P8608 | Fatcat ID | release_6i7j2dipnvbavfu65vc77szub4 |
| P698 | PubMed publication ID | 15378439 |
| P5875 | ResearchGate publication ID | 8337331 |
| P50 | author | Russell E. Lewis | Q38327565 |
| Nathan Paul Wiederhold | Q42104169 | ||
| Dimitrios P Kontoyiannis | Q88469665 | ||
| P2093 | author name string | Vincent H Tam | |
| Jingduan Chi | |||
| Randall A Prince | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| pharmacodynamics | Q725307 | ||
| invasive pulmonary aspergillosis | Q54946623 | ||
| murine model | Q122890741 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1464-1471 | |
| P577 | publication date | 2004-09-10 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity | |
| P478 | volume | 190 |
| Q37653647 | A clinical review of echinocandins in pediatric patients |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q49792124 | A new marker of echinocandins activity in an in vitro PK/PD model correlates with an animal model of Aspergillus fumigatus infection |
| Q28476705 | A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design |
| Q42731827 | Anidulafungin and its role in candida infections |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q36822941 | Anidulafungin in the treatment of invasive fungal infections |
| Q37827345 | Anidulafungin: an evidence-based review of its use in invasive fungal infections. |
| Q35663841 | Antifungal pharmacokinetics and pharmacodynamics |
| Q37816399 | Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients |
| Q40668367 | Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. |
| Q42157206 | Bronchopulmonary disposition of micafungin in healthy adult volunteers |
| Q34449662 | Calcineurin as a Multifunctional Regulator: Unraveling Novel Functions in Fungal Stress Responses, Hyphal Growth, Drug Resistance, and Pathogenesis |
| Q36747015 | Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus |
| Q38676508 | Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis |
| Q41990022 | Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. |
| Q39701953 | Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections |
| Q33805542 | Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis |
| Q36983268 | Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. |
| Q37854725 | Caspofungin therapy in immunocompromised children and neonates |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q36257157 | Caspofungin: a review of its use in the treatment of fungal infections |
| Q41929256 | Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q35758926 | Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. |
| Q36422666 | Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia |
| Q42075610 | Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis |
| Q34596761 | Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis |
| Q28273738 | Comparison of echinocandin antifungals |
| Q35647724 | Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species |
| Q35840760 | Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model |
| Q36845482 | Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. |
| Q37908856 | Current concepts in antifungal pharmacology |
| Q37151326 | Current options in antifungal pharmacotherapy. |
| Q37554055 | Current perspectives on echinocandin class drugs |
| Q35666612 | Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections |
| Q36924037 | Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. |
| Q40587101 | Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis |
| Q33366929 | Early-onset heparin-induced thrombocytopenia after a 165-day heparin-free interval: case report and review of the literature |
| Q37822777 | Echinocandin antifungal drugs in fungal infections: a comparison |
| Q37718385 | Echinocandin pharmacodynamics: review and clinical implications. |
| Q92354498 | Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside |
| Q39458862 | Echinocandins in antifungal pharmacotherapy. |
| Q38633102 | Echinocandins: The Expanding Antifungal Armamentarium |
| Q34352222 | Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. |
| Q36295480 | Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopy |
| Q39705805 | Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig. |
| Q34077069 | Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. |
| Q40916536 | Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice. |
| Q42286250 | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. |
| Q36949553 | Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis |
| Q39565084 | Efficacy of the investigational echinocandin ASP9726 in a guinea pig model of invasive pulmonary aspergillosis |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q42104497 | Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. |
| Q37291442 | Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility |
| Q37159589 | Experiences with the use of caspofungin in paediatric patients |
| Q92575576 | Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus |
| Q90577176 | Extrapolating Antifungal Animal Data to Humans - Is it reliable? |
| Q41848811 | Fungal echinocandin resistance. |
| Q58033533 | Glucan Synthase Inhibitors |
| Q38173720 | High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events |
| Q51186226 | High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. |
| Q35860061 | Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus |
| Q41857220 | In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus |
| Q42909091 | In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin |
| Q33876423 | In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species |
| Q36425025 | In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. |
| Q43076592 | In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin |
| Q34721750 | Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection |
| Q36425073 | Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. |
| Q34045450 | Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q34108585 | Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections |
| Q40196214 | Lung eosinophil recruitment in response to Aspergillus fumigatus is correlated with fungal cell wall composition and requires γδ T cells. |
| Q36482785 | Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans |
| Q36120798 | Micafungin: pharmacology, experimental therapeutics and clinical applications |
| Q52575146 | Ocular penetration of caspofungin in a rabbit uveitis model. |
| Q35647785 | Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia |
| Q37405284 | Paradoxical echinocandin activity: a limited in vitro phenomenon? |
| Q42747700 | Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences |
| Q34352109 | Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis |
| Q38919690 | Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. |
| Q34228214 | Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity |
| Q33757912 | Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. |
| Q37785979 | Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections |
| Q34123805 | Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents |
| Q57746174 | Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins |
| Q37624716 | Pharmacological properties of antifungal drugs with a focus on anidulafungin |
| Q37359613 | Pharmacology and antifungal properties of anidulafungin, a new echinocandin |
| Q38942828 | Potential Microbiological Effects of Higher Dosing of Echinocandins. |
| Q35647688 | Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice |
| Q36641630 | Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis |
| Q91876531 | Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans |
| Q49679966 | Recent Insights into the Paradoxical Effect of Echinocandins |
| Q36849595 | Resistance to echinocandin-class antifungal drugs |
| Q33689767 | Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization. |
| Q36171611 | Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis |
| Q37209970 | Stage-specific innate immune recognition of Aspergillus fumigatus and modulation by echinocandin drugs. |
| Q33601917 | Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi |
| Q37396221 | The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. |
| Q36742397 | The echinocandins |
| Q36626518 | The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications |
| Q36788428 | The pharmacology and clinical use of caspofungin |
| Q35076940 | The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus. |
| Q42910122 | Trailing or paradoxical growth of Candida albicans when exposed to caspofungin is not associated with microsatellite genotypes |
| Q37443093 | Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus |
| Q39895162 | Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin |
| Q34933267 | Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia |
| Q81533852 | [In vitro activity of the echinocandins. How should it be evaluated?] |
| Q45942595 | [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins]. |
Search more.